http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102492657-B
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_de2c2827145c62d3e0e6e1207efddae0 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-66 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-11 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-63 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N21-64 |
| filingDate | 2011-12-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2015-02-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_058b1796d1ad584a8fe703ce03a708ec http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_594a6516cc1f7b7ff4eac2c106f08013 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2b20c3ec59a3620fcd001eafeb1cd8ba http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6c023751901a825e1525f05585a1f802 |
| publicationDate | 2015-02-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-102492657-B |
| titleOfInvention | Drug screening cell model using NF-kappa B as target and building and applications thereof |
| abstract | The invention provides a drug screening cell model using nuclear factor (NF)-kappa B as the target, belonging to the biomedical field. The model is built on the basis of the active cells of constitutive NF-kappa B by using a reporting system carrier containing a NF-kappa B specific combination sequence and is used to screen drugs for curing the tumors and immunity diseases which are caused by the activation of the constitutive NF-kappa B. As the active cells of the constitutive NF-kappa B are adopted, the reporter gene in the modal cell is in a highly activated state and no external irritant is required; the obtained stable cell model can be directly used in the screening of compounds, thus the screening cost is greatly reduced, the entire screening flow is simplified, the screening cycle is shortened, the operating steps are reduced, the stability, high efficiency and usability of the system are increased; and the cell model is more suitable for high throughput drug screening. The original entire screening flow comprises the following steps: culturing cells, activating NF-kappa B, adding compounds and detecting. The simplified screening flow comprises the following steps: culturing cells, adding compounds and detecting. |
| priorityDate | 2011-12-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 71.